AMASS - Downloads

We revised the text and corrected bugs encountered during data import and translation.
We updated SaTScan codes for "AnnexC: Cluster signals" and report layouts.

AMASS version 3.0

- Released on 30 April 2024

Description:

We added "Annex C: Cluster signals". This annex shows potential clusters of patients with AMR infection identified using the SaTScan (www.satscan.org).
We kept processed (i.e. de-duplicated and/or merged) data files in the folder named "Report with patient identifiers" for any further analysis and internal use after using the AMASS.
We included Enterococcus faecalis and E. faecium in the pathogens under the surveillance.
We added additional antibiotics in the lists for some pathogens under the surveillance.
We improved algorithms for supporting data importation, translation, and exportation in a large data set.
We used only Python rather than R + Python (as used in the AMASS version 2.0).
We set a default config for infection-origin stratification by consifering a specimen collected two calendar days before the hospital admission date and a specimen collected one day after the hospital discharge date. This config supports the real-world setting that several hospitals in LMICs (particularly Thailand) have patients stay in the hospital (e.g. at ER) due to many limitations before the official admissions can be made.
We improved the algorithm for estimating "bed-days at risk" and "bed-days at risk for hospital-origin infection" by including patients who were not yet discharged from the hospital (i.e. having discharge dates after the evaluation period) in the analysis.

AMASS version 3.0 (BETA) Build 3026

- Released on 10 January 2024

Description:

We included Thai language displays in the verification logfile report.
We added tables in verification logfile report for verifying ward translation process from microbiology data file (Table S10A) and hospital admission data file (Table S10B).

AMASS version 3.0 (BETA) Build 3022

- Released on 4 December 2023

Description:

We added "Annex C: Cluster signals". This annex shows potential clusters of patients with AMR infection identified using the SaTScan (www.satscan.org).
We kept and exported processed (i.e. de-duplicated and/or merged) data files for any further analysis and internal use after using the AMASS.
We included Enterococcus faecalis and E. faecium in the pathogens under the surveillance.
We added additional antibiotics in the lists for some pathogens under the surveillance.
We improved algorithms for supporting data importation, translation, and exportation in a large data set.
We used only Python rather than R + Python (as used in the AMASS version 2.0).
We improved the algorithm for estimating "bed-days at risk" and "bed-days at risk for hospital-origin infection" by including patients who were not yet discharged from the hospital (i.e. having discharge dates after the evaluation period) in the analysis.

AMASS version 2.0

- Released on 16 November 2022

Description:

We fixed a typo in the R code that caused inaccurate estimations of the proportion of patients with non-susceptible isolates against levofloxacin and carbapenem drugs.
We included Acinetobacter baumanii in the pathogens under the surveillance as default.
We set an option for users to choose whether A. baumanii (default) or Acinetobacter spp. will be included for AMR Surveillance Report.

AMASS version 2.0

- Released on 16 May 2022

Description:

We implemented from AMASSplus that was released on 25 Mar 2021.
We added "AnnexA: notifiable bacterial infections" and "AnnexB: Data indicators" (including proportion of contaminants and discordant AST results).
We generated supplementary data indictor report to support users for verifying and validating data.

AMASSplus

- Released on 25 Mar 2021

Description:

We implemented from AMASS version 1.1 that was released on 25 Mar 2021.
We added AnnexA: notifiable bacterial infections.

AMASS version 1.1

- Released on 12 Jan 2021

Description:

We implemented from AMASS version 1.0.
We corrected bugs encountered estimations of the proportion of non-susceptible isolates of Escherichia coli and Klebsiella pneumoniae for ampicillin.

Version Beta 12102019

- Released on 12 Oct 2019

Description:

We implemented from AMASS version beta 26022019.
We implemented 6 completed sections including [1] Data overview; [2] Isolated-based surveillance report without stratification by infection origin; [3] Isolated-based surveillance report with stratification by infection origin; [4] Sample-based surveillance report without stratification by infection origin; [5] Sample-based surveillance report with stratification by infection origin; and [6] Mortality in AMR and antimicrobial-susceptible infections.
We corrected bugs found from the previous version.

Version Beta 26022019

- Released on 16 Feb 2019

Description:

This is the first released version of AMASS that contained 4 main sections. The sections are [1] General demographic data; [2] Isolated-based surveillance report without stratification by infection origin; [3] Isolated-based surveillance report with stratification by infection origin; and [5] Mortality in AMR and antimicrobial-susceptible infections. Please note that in this version, Section [4] on Sample-based surveillance report was under development (incomplete).

The content of this site is © 2019 MORU but may be used under the terms of the Creative Commons Attribution Non-Commercial Licence which permits unrestricted use, distribution, and reproduction for non-commercial purposes and provided the original work is properly cited.